International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

被引：0
|
作者：
Matveev, V. B. [1 ]
Khalmurzaev, O. A. [1 ]
Evsyukova, O., I [1 ]
机构：
[1] Minist Hlth Russia, NN Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoe Shosse, Moscow 115478, Russia
来源：
ONKOUROLOGIYA | 2020年 / 16卷 / 04期
关键词：
prostate cancer; HRR mutations; BRCA; olaparib; DNA-REPAIR;
D O I：
10.17650/1726-9776-2020-16-4-197-206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.
引用
收藏
页码：197 / 206
页数：10
相关论文
共 50 条
  • [1] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Cumberbatch, Marcus
    Condon, Benjamin
    Lawrentschuk, Nathan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2021, 79 (02) : 319 - 320
  • [2] Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
    LeVee, Alexis
    Lin, Ching Ying
    Posadas, Edwin
    Figlin, Robert
    Bhowmick, Neil A.
    Di Vizio, Dolores
    Ellis, Leigh
    Rosser, Charlos J.
    Freeman, Michael R.
    Theodorescu, Dan
    Freedland, Stephen J.
    Gong, Jun
    ONCOTARGETS AND THERAPY, 2021, 14 : 4819 - 4832
  • [3] Drug approval: Olaparib in combination with abiraterone for metastatic castration-resistant prostate cancer
    Sabouret, Annabelle
    Beuzeboc, Philippe
    BULLETIN DU CANCER, 2023, 110 (04) : 339 - 341
  • [4] Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective
    Matsumoto, Takashi
    Shiota, Masaki
    Blas, Leandro
    Eto, Masatoshi
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2389 - 2397
  • [5] Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer
    Mourmouris, Panagiotis
    Papatsoris, Athanasios
    Dellis, Athanasios
    Mitsogiannis, Iraklis
    Abou Chakra, Mohamed
    Moussa, Mohamad
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (15) : 1955 - 1959
  • [6] Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation
    Saillant, Arnaud
    Flippot, Ronan
    BULLETIN DU CANCER, 2021, 108 (02) : 140 - 142
  • [7] Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer
    Martini, Alberto
    Fallara, Giuseppe
    Ploussard, Guillaume
    Malavaud, Bernard
    LANCET ONCOLOGY, 2023, 24 (10) : 1056 - 1057
  • [8] Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?
    Fenton, Sarah E.
    Hussain, Maha
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (10) : 993 - 999
  • [9] Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer
    Zhu, Jason
    Tucker, Matthew
    Wang, Endi
    Grossman, Joel S.
    Armstrong, Andrew J.
    George, Daniel J.
    Zhang, Tian
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : E1137 - E1141
  • [10] Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
    Fallara, Giuseppe
    Robesti, Daniele
    Raggi, Daniele
    Montorsi, Francesco
    Necchi, Andrea
    Cooperberg, Matthew R.
    Malavaud, Bernard
    Ploussard, Guillaume
    Martini, Alberto
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 52 : 40 - 43
12345